Michelle J Henderson

List of Publications by Year
in descending order

21 papers	1,625 citations	686830 13 h-index	752256 20 g-index
21 all docs	21 docs citations	21 times ranked	3337 citing authors

#	Article	IF	Citations
1	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. British Journal of Cancer, 2022, 126, 482-491.	2.9	7
2	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. British Journal of Cancer, 2022, 127, 908-915.	2.9	2
3	Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. British Journal of Cancer, 2021, 125, 55-64.	2.9	16
4	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clinical Cancer Research, 2021, 27, 4338-4352.	3.2	14
5	Analytical Quality Controls for ddPCR Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. Clinical Chemistry, 2021, 67, 1373-1383.	1.5	0
6	Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia. Frontiers in Oncology, 2021, 11, 779859.	1.3	3
7	Potent antileukemic activity of curaxin CBL0137 against MLLâ€rearranged leukemia. International Journal of Cancer, 2020, 146, 1902-1916.	2.3	30
8	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia, 2020, 34, 1524-1539.	3.3	20
9	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia, 2020, 34, 1828-1839.	3.3	37
10	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYCâ€“Driven Cancer Progression. Cancer Research, 2020, 80, 3706-3718.	0.4	15
11	<scp>ABCC4</scp>/<scp>MRP4</scp> contributes to the aggressiveness of Mycâ€associated epithelial ovarian cancer. International Journal of Cancer, 2020, 147, 2225-2238.	2.3	11
12	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	2.6	17
13	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research, 2017, 77, 971-981.	0.4	90
14	CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget, 2016, 7, 46067-46087.	0.8	12
15	Effective Targeting of the P53â€“MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 1395-1405.	3.2	43
16	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology, 2014, 91, 97-108.	2.0	53
17	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. Journal of the National Cancer Institute, 2011, 103, 1236-1251.	3.0	113
18	ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer, 2010, 10, 147-156.	12.8	920

#	Article	IF	Citations
19	Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells. Journal of Biological Chemistry, 2010, 285, 19532-19543.	1.6	96
20	Mechanism of relapse in pediatric acute lymphoblastic leukemia. Cell Cycle, 2008, 7, 1315-1320.	1.3	25
21	Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood, 2007, 110, 632-639.	0.6	101